Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL34250 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL13287212 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL41214 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157427 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1319766 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL29424282 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157381 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL11215595 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL16241872 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL3136078 | 0.94 | GFER (0.91) | DRD1DRD2KDM4ERECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3038614-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-07-06 | — | — | EP | disclosed |
| EP-2892519-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015028659-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014037412-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2496226-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | Pharnext (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012117073-A2 | NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011054759-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | PHARNEXT (FR) | 2011-05-12 | — | — | WO | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |